title: Prevention of joint destruction in patients with high disease activity or high C-reactive protein levels: Post hoc analysis of the GO-FORTH study.
abstract: OBJECTIVE
  To assess the influence of golimumab dosage and disease activity on joint destruction in patients with active rheumatoid arthritis (RA) in the GO-FORTH study.
  
  
  METHODS
  Efficacy was compared among groups given basal methotrexate plus placebo, golimumab (50 mg), or golimumab (100 mg) with stratification by high (HDA) or moderate (MDA) baseline disease activity and by high or low baseline C-reactive protein (CRP).
  
  
  RESULTS
  Among HDA or high CRP patients, the mean change of the total Sharp score was 3.48 and 3.41 in the placebo group, 1.94 and 2.71 in the 50 mg group, and 0.39 and 1.15 in the 100 mg group, respectively. The percentage of progression-free patients with HDA or high CRP was 40.4% and 40.0%, 43.1% and 38.2%, and 69.8% and 61.5%, respectively. Among MDA or low CRP patients, both golimumab doses showed similar prevention of joint destruction. Among HDA or high CRP patients, a shorter disease duration and higher TSS/disease duration ratio were associated with joint destruction.
  
  
  CONCLUSIONS
  Both doses of golimumab (50 or 100 mg) prevented joint destruction in MDA or low CRP patients, but 100 mg was better for HDA or high CRP patients with a shorter disease duration or higher TSS/disease duration ratio.
authors.affiliation: a The First Department of Internal Medicine, University of Occupational and Environmental Health Japan , Kitakyushu , Fukuoka , Japan .
authors.forename: Yoshiya
authors.initials: Y
authors.lastname: Tanaka
authors.affiliation: b Department of Medicine and Rheumatology, Tokyo Medical and Dental University , Bunkyo-Ku , Tokyo , Japan .
authors.forename: Masayoshi
authors.initials: M
authors.lastname: Harigai
authors.affiliation: c Department of Internal Medicine, Keio University , Shinjuku-Ku , Tokyo , Japan .
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Takeuchi
authors.affiliation: d Institute of Rheumatology, Tokyo Women's Medical University , Shinjuku-Ku , Tokyo , Japan .
authors.forename: Hisashi
authors.initials: H
authors.lastname: Yamanaka
authors.affiliation: e Department of Orthopedic Surgery, Nagoya University, Graduate School and Faculty of Medicine , Nagoya , Japan .
authors.forename: Naoki
authors.initials: N
authors.lastname: Ishiguro
authors.affiliation: f Department of Allergy and Rheumatology, The University of Tokyo , Bunkyo-Ku , Tokyo , Japan .
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Yamamoto
authors.affiliation: g Janssen Pharmaceutical K.K. , Chiyoda-Ku , Tokyo , Japan .
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Ishii
authors.affiliation: g Janssen Pharmaceutical K.K. , Chiyoda-Ku , Tokyo , Japan .
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakajima
authors.affiliation: h Janssen Research and Development, LLC , Spring House , PA , USA .
authors.forename: Daniel
authors.initials: D
authors.lastname: Baker
authors.affiliation: i Department of Medicine and Rheumatology, Tokyo Medical and Dental University , Bunkyo-Ku , Tokyo , Japan , and.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Miyasaka
authors.affiliation: j Sapporo Medical Center NTT EC , Sapporo , Japan.
authors.forename: Takao
authors.initials: T
authors.lastname: Koike
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000097:blood / Q000188:drug therapy*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D008875:Middle Aged; D012720:Severity of Illness Index; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D015415:Biomarkers; D002097:C-Reactive Protein; C529000:golimumab; D008727:Methotrexate
keywords: Golimumab; High disease activity; Japanese; Rheumatoid arthritis; Total Sharp score